RESEARCHER PROFILE

Selım Gürel

← Back to Bursa Uludağ Üni̇versi̇tesi̇

S

Bursa Uludağ Üni̇versi̇tesi̇

Hepatitis C virus researchHepatitis B Virus StudiesLiver Disease Diagnosis and TreatmentHelicobacter pylori-related gastroenterology studiesLiver Disease and Transplantation

Selım Gürel works in Hepatitis C virus research, Hepatitis B Virus Studies, Liver Disease Diagnosis and Treatment, Helicobacter pylori-related gastroenterology studies, Liver Disease and Transplantation. Recorded institutional associations include Bursa Uludağ Üni̇versi̇tesi̇.

202Publications
5,081Citations
26H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B

    2004 · 1,145 citations
  2. Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta

    2011 · 488 citations
  3. Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B

    2010 · 462 citations
  4. Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a

    2009 · 315 citations
  5. Late HDV RNA Relapse After Peginterferon Alpha-Based Therapy of Chronic Hepatitis Delta

    2014 · 301 citations
  6. Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection

    2014 · 297 citations
  7. Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

    2006 · 261 citations
  8. Impact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B

    2015 · 212 citations
  9. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial

    2019 · 199 citations
  10. Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B

    2013 · 148 citations
  11. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis

    2009 · 120 citations
  12. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate

    2014 · 116 citations
  13. Famciclovir treatment of chronic delta hepatitis

    2002 · 111 citations
  14. Ten‐year follow‐up of a randomized controlled clinical trial in chronic hepatitis delta

    2020 · 80 citations
  15. Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta

    2014 · 68 citations
  16. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome

    2015 · 66 citations
  17. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study

    2016 · 62 citations
  18. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years

    2015 · 60 citations
  19. Is severe cryptogenic chronic hepatitis similar to autoimmune hepatitis?

    1998 · 59 citations
  20. O4 PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-α-2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDY

    2014 · 57 citations
  21. TWO YEAR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT AND ADEFOVIR DIPIVOXIL (ADV) SWITCH DATA IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102), PRELIMINARY ANALYSIS

    2008 · 57 citations
  22. 43 LONG TERM TENOFOVIR DISOPROXIL FUMARATE (TDF) THERAPY AND THE RISK OF HEPATOCELLULAR CARCINOMA

    2013 · 37 citations
  23. Pegylated Interferon Alfa-2b Monotherapy and Pegylated Interferon Alfa-2b plus Lamivudine Combination Therapy for Patients with Hepatitis B Virus E Antigen-Negative Chronic Hepatitis B

    2007 · 36 citations
  24. Anti-Hdv Immunoglobulin M Testing in Hepatitis Delta Revisited: Correlations with Disease Activity and Response to Pegylated Interferon-α2A Treatment

    2011 · 32 citations
  25. 924 INCREASING RATES OF HBsAg CLEARANCE AND SEROCONVERSION IN PATIENTS WITH HBeAg-NEGATIVE DISEASE TREATED WITH PEGINTERFERON ALFA-2A ± LAMIVUDINE: RESULTS OF 5-YEAR POST-TREATMENT FOLLOW UP

    2009 · 27 citations

← Return to the university profile